Semintra

Telmisartan, the active ingredient in Semintra, is an angiotensin II receptor blocker presented as a tablet for oral use. It is indicated for the management of hypertension and for lowering cardiovascular risk in adult patients with established vascular disease or multiple risk factors.

GNH USA supplies Semintra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medication for healthcare providers across global markets.

Semintra (telmisartan) acts on the renin‑angiotensin‑aldosterone system to control high blood pressure.

Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension. Cardiovascular risk reduction: decreases the incidence of major cardiovascular events in high‑risk adults. Stroke prevention: reduces the risk of stroke in patients with a history of cerebrovascular disease.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue or tiredness. - Elevated blood potassium levels. - Mild gastrointestinal discomfort. - Increased serum creatinine.

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue or airway. - Severe hypotension causing fainting. - Acute kidney injury or worsening renal function. - Hepatic injury with jaundice. - Severe allergic reactions such as rash or eosinophilia.

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly: ensure target levels are achieved without excessive drop. - Assess renal function: check serum creatinine and eGFR before and during treatment. - Check electrolytes: especially potassium, to avoid hyperkalaemia. - Use caution in severe hepatic impairment: dose adjustment may be required. - Avoid use during pregnancy: potential fetal toxicity. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Telmisartan may interact with several medicines; awareness of these interactions helps maintain safety.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment and hyperkalaemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - ACE inhibitors: combined use can lead to excessive potassium rise and renal dysfunction. - Lithium: telmisartan can raise lithium concentrations, risking toxicity. - NSAIDs: concurrent use may impair renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Other antihypertensives: additive blood pressure lowering. - CYP2C9 inhibitors (e.g., fluconazole): may increase telmisartan plasma levels. - Antacids containing aluminium or magnesium: may reduce absorption if taken simultaneously. - Warfarin: monitor INR as telmisartan can affect anticoagulant control.